Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy

NCT00343720 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: VELCADE
DRUG: Alimta

Sponsor

Millennium Pharmaceuticals, Inc.

Collaborators

[object Object]